F-star Therapeutics Profit Margin

F-star Therapeutics's profit margin stands at -2.12% as of September 2022. That compares with -11.71% in the prior-year period — up 81.9% year over year. That is below the Healthcare sector average of 15.58%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

F-star Therapeutics reported -2.12% in profit margin versus -11.71% a year earlier — a 81.9% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

F-star Therapeutics sits lower the Healthcare benchmark (15.58%) with a profit margin of -2.12%. That is roughly 1463.4% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of -2.12% for F-star Therapeutics means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how F-star Therapeutics's profit margin evolved across reporting periods, while the comparison chart places FSTX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.